Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | QPCT | Q16769 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643046 | 0.88 | FGFR1 (0.50) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| SCHEMBL10603795 | 0.81 | MTNR1A (0.59) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| Bromide SCHEMBL29624933 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| SCHEMBL19848085 | 0.80 | TNF (0.44) | ALDH1A1HPGDHTTMAPK1TBXA2R | |
| SCHEMBL19911355 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| SCHEMBL19911346 | 0.79 | MTNR1A (0.64) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| SCHEMBL19611398 | 0.78 | MTNR1A (0.62) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| SCHEMBL12479984 | 0.78 | MTNR1A (0.62) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| SCHEMBL12479232 | 0.78 | MTNR1A (0.66) | MTNR1AMTNR1BALDH1A1HPGDHTT | |
| SCHEMBL9120412 | 0.78 | MTNR1A (0.62) | MTNR1AMTNR1BALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0271260-B1 | Supersensitization of silver halide emulsions | MINNESOTA MINING & MFG (US) | 1995-01-04 | — | — | EP | claimed |
| US-4873184-A | ADDITION OF A METAL COMPLEXING AGENT TO THE EMULSION; HIGH SPEED | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-10-10 | — | — | US | claimed |
| EP-0271260-A2 | Supersensitization of silver halide emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-06-15 | — | — | EP | claimed |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-08-25 | — | — | US | disclosed |
| EP-3467930-B1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
| EP-3279997-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY | Asahi Kasei Kabushiki Kaisha (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-20030216582-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | NIKOLAIDES NICHOLAS (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030087943-A1 | 2-phencycarbamoyl-benzimidazoles | NIKOLAIDES NICHOLAS (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1263736-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | THE PROCTER & GAMBLE COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001058878-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-0271260-B1 | Supersensitization of silver halide emulsions | MINNESOTA MINING & MFG (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5013622-A | Supersensitization of silver halide emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
| US-4873184-A | ADDITION OF A METAL COMPLEXING AGENT TO THE EMULSION; HIGH SPEED | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0271260-A2 | Supersensitization of silver halide emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216582-A1 | 2-CARBOXAMIDE-BENZIMIDAZOLES USEFUL IN THE TREATMENT AND PREVENTION OF ISCHEMIC REPERFUSION INJURY | CBR3, BAK1, CBR1 | MTNR1A 349/4885MTNR1B 436/4885ALDH1A1 428/4885 |
| US-20030087943-A1 | 2-phencycarbamoyl-benzimidazoles | BRI3BP, CBR3, H1-3 | MTNR1A 1692/4885MTNR1B 904/4885ALDH1A1 1676/4885 |
| US-10756394-B2 | Nonaqueous electrolyte and nonaqueous secondary battery | BPTF, BRD4, KCNN2 | MTNR1A 4313/4885MTNR1B 4134/4885ALDH1A1 3497/4885 |
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | MTNR1A 4313/4885MTNR1B 4134/4885ALDH1A1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.